Form 4 for BIIB Biogen
Accepted 2025-02-12 00:00:00 ET · period of report 2025-02-10 · accession 0001127602-25-004452 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-12 | 2025-02-10 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | +1,515 | 8,998 | +20% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | Izzar Rachid | Head of Gbl Product Strat | F - Tax | $142.54 | -445 | 8,553 | -5% | -$63.4K |
| D | 2025-02-12 | 2025-02-10 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | -1,515 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-10 | M | A | 1,515 | $0.00 | 8,998 | D | — | — | (F1) Total adjusted to reflect transfer of shares to the reporting person's former spouse pursuant to a Domestic Relations Order. |
| 2 | Common | Common Stock | 2025-02-10 | F | D | 445 | $142.54 | 8,553 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2025-02-10 | M | D | 1,515 | $0.00 | 0 | D | $0.00 · — to 2025-02-10 | 1,515 Common Stock | (F2) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. |